{"id":"W3081126751","doi":"10.1200/jco.2009.27.15_suppl.3526","title":"Phase II trial of pharmacodynamically (PDally)-guided optimal biologic dose titration (OBDT) of sorafenib (S) in combination with metronomic cyclophosphamide (mC) in advanced neuroendocrine tumors (aNET)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Sorafenib; Toxicity; Cyclophosphamide; Pharmacology; Internal medicine; Urology; Oncology; Chemotherapy; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001826628,0.0002374739,0.002196388,0.000655898,0.00002228385,0.000004722986,0.000321154,0.00004844018,0.00005390522],"category_scores_gemma":[0.004910959,0.0001767256,0.0003080464,0.0005704027,0.0003305978,0.0003326734,0.00006132293,0.001313085,0.000001529648],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002384954,"about_ca_system_score_gemma":0.001420533,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002396396,"about_ca_topic_score_gemma":0.00006164668,"domain_scores_codex":[0.9935895,0.0008180737,0.004276427,0.0003385677,0.0005452468,0.0004321761],"domain_scores_gemma":[0.9946471,0.001544228,0.002848986,0.0002312106,0.000442676,0.0002857644],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7290134,0.05053348,0.01103975,0.00010326,0.0001626721,0.01278536,0.00004824778,0.007727864,0.07105999,0.0003539641,0.0001772868,0.1169947],"study_design_scores_gemma":[0.5770485,0.3413583,0.05985561,0.0002312385,0.0001611978,0.001263849,0.00008068065,0.002998634,0.01524851,0.0005865965,0.0009585657,0.0002083184],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9940311,0.0001512395,0.00005570976,0.004003166,0.0002997536,0.001058076,0.000004785421,0.00001117234,0.0003849559],"genre_scores_gemma":[0.9933873,0.0007624243,0.005221341,0.0003687825,0.000167326,0.00001164163,0.00001152906,0.00001828573,0.00005141053],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2908248,"threshold_uncertainty_score":0.7206659,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06726536667610367,"score_gpt":0.4714642139511911,"score_spread":0.4041988472750875,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}